Cargando…

Corticosteroid Use and Adherence in Patients Treated with Acthar Gel for Advanced Sarcoidosis

INTRODUCTION: Long-term corticosteroid use in immune-mediated diseases is associated with increased risk of adverse events (AEs) and worsened health-related quality of life (HRQoL). Previous studies report chronic high-dose corticosteroid therapy results in higher rates of healthcare resource use an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hayes, Kyle, Niewoehner, John, Rice, J. Bradford, Downes, Nathaniel, Hagopian, Ella, Ma, Izzy, Wan, George J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567815/ https://www.ncbi.nlm.nih.gov/pubmed/37728695 http://dx.doi.org/10.1007/s12325-023-02630-x

Ejemplares similares

Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis
por: Bindra, Jas, et al.
Publicado: (2023)

Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence
por: Wan, George J, et al.
Publicado: (2023)

Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus
por: Bindra, Jas, et al.
Publicado: (2022)

Healthcare Costs and Resource Utilization in Patients with Infantile Spasms Treated with H.P. Acthar Gel(®)
por: Gold, Laura S., et al.
Publicado: (2016)

Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel
por: Zhou, Ying, et al.
Publicado: (2015)

Acthar Gel Inhibits the Activation of CD4(+) and CD8(+) T Cells
por: Wright, Dale, et al.
Publicado: (2023)

A Narrative Review of Acthar Gel for the Treatment of Myositis
por: Chandra, Tanya, et al.
Publicado: (2023)

Direct effects of HP Acthar Gel(®) on human B lymphocyte activation in vitro
por: Olsen, Nancy J., et al.
Publicado: (2015)

Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®)
por: Gold, Laura S., et al.
Publicado: (2016)

Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series
por: Madan, Arvind, et al.
Publicado: (2016)

Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis
por: Bindra, Jas, et al.
Publicado: (2022)

H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes
por: Kutz, Christen
Publicado: (2016)

Acthar(®) Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence
por: Kaplan, Jeffrey, et al.
Publicado: (2023)

Safety and Efficacy of Combination ACTHar Gel and Tacrolimus in Treatment-Resistant Focal Segmental Glomerulosclerosis and Membranous Glomerulopathy
por: Tumlin, James, et al.
Publicado: (2017)

A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse
por: Kaplan, Jeffrey, et al.
Publicado: (2020)

Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis
por: Rice, J. Bradford, et al.
Publicado: (2020)

Membranous glomerulopathy and treatment with Acthar®: a case study
por: Watson, Myra June
Publicado: (2013)

Use of Repository Corticotropin Gel (Acthar) in Progressive Nephrotic Syndrome Secondary to Transplant Glomerulopathy: A Report of Three Cases
por: Markell, Mariana, et al.
Publicado: (2019)

ACTH (Acthar Gel) Reduces Toxic SOD1 Protein Linked to Amyotrophic Lateral Sclerosis in Transgenic Mice: A Novel Observation
por: Arrat, Hasan, et al.
Publicado: (2015)

A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy
por: Hladunewich, Michelle A., et al.
Publicado: (2014)

Sarcoidosis or Tuberculosis: Should Corticosteroids Be Used?
por: Shen, Yuting, et al.
Publicado: (2023)

Repository Corticotropin Injection (Acthar(®) Gel) for Refractory Severe Noninfectious Keratitis: Efficacy and Safety from a Phase 4, Multicenter, Open-Label Study
por: Wirta, David, et al.
Publicado: (2021)

Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review
por: Girman, Cynthia, et al.
Publicado: (2022)

Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar(®) Gel) for Persistently Active Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2021)

Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial
por: Askanase, Anca D, et al.
Publicado: (2020)

Long‐Term Corticosteroid‐Sparing Immunosuppression for Cardiac Sarcoidosis
por: Rosenthal, David G., et al.
Publicado: (2019)

Real-World Treatment Patterns and Outcomes from an Electronic Medical Records Database for Patients with Rheumatoid Arthritis Treated with Repository Corticotropin Injection
por: Hayes, Kyle, et al.
Publicado: (2021)

Spontaneous improvement of laryngeal sarcoidosis resistant to systemic corticosteroid administration
por: Tsubouchi, Kazuya, et al.
Publicado: (2015)

Cumulative Incidence and Predictors of Progression in Corticosteroid-Naïve Patients with Sarcoidosis
por: Inoue, Yusuke, et al.
Publicado: (2015)

Corticosteroid and Immunosuppressant Therapy for Cardiac Sarcoidosis: A Systematic Review
por: Fazelpour, Siavosh, et al.
Publicado: (2021)

Cardiac sarcoidosis: systematic review of the literature on corticosteroid and immunosuppressive therapies
por: Stievenart, Julien, et al.
Publicado: (2022)

Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2021)

Corticosteroid Therapy Improves the Outcome of Semen Analysis in an Oligozoospermic Patient With Epididymal Sarcoidosis
por: Canguven, Onder, et al.
Publicado: (2013)

The Risk of Sarcoidosis Misdiagnosis and the Harmful Effect of Corticosteroids When the Disease Picture Is Incomplete
por: Arcana, Raluca Ioana, et al.
Publicado: (2023)

Low dose corticosteroid in association with methotrexate for therapy of ocular sarcoidosis: report of a case
por: Mayer, Grasiane Nunes, et al.
Publicado: (2015)

Recovery of High Degree Atrioventricular Block in a Patient with Cardiac Sarcoidosis by Corticosteroid Therapy
por: Park, Hyukjin, et al.
Publicado: (2018)

Complete heart block in cardiac sarcoidosis reversed by corticosteroid therapy: time course of resolution
por: Tomdio, Anna, et al.
Publicado: (2021)

Medical adherence to intranasal corticosteroids in adult patients()
por: Ocak, Emre, et al.
Publicado: (2016)

Adherence to inhaled corticosteroids by asthmatic patients: measurement and modelling
por: Taylor, Amelia, et al.
Publicado: (2013)

Self-reported vs. objectively assessed adherence to inhaled corticosteroids in asthma
por: Jensen, Frodi Fridason, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_npamudd1raeoome088pruam2ll